Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Avacta Life Sciences Ltd
Beijing Biotech
National Institutes of Health Clinical Center (CC)
AbbVie
Merck Sharp & Dohme LLC
Pfizer
Seagen Inc.
Zai Lab (Hong Kong), Ltd.
PMV Pharmaceuticals, Inc
Big Ten Cancer Research Consortium
National Institutes of Health Clinical Center (CC)
VA Office of Research and Development
Kivu Bioscience Inc.
University Health Network, Toronto
BeOne Medicines
Akeso
University of Chicago
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Bristol-Myers Squibb
Sun Yat-sen University
Palo Alto Veterans Institute for Research
Neonc Technologies, Inc.
Daiichi Sankyo
AstraZeneca
Eli Lilly and Company
Amgen
Amgen
Novartis
Radiopharm Theranostics, Ltd
Puma Biotechnology, Inc.
Alliance Foundation Trials, LLC.
BioNTech SE
Memorial Sloan Kettering Cancer Center
NiKang Therapeutics, Inc.
BioNTech SE
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC
Boehringer Ingelheim
UNC Lineberger Comprehensive Cancer Center
MacroGenics
Amgen
Fundación GECP
Henry Ford Health System
SystImmune Inc.
China Medical University, China
PrECOG, LLC.
IDEAYA Biosciences
SWOG Cancer Research Network
Nantes University Hospital